OBJECTIVES: Quantitative electroencephalogram (qEEG) can be used to measure the effects of drugs on the brain. We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia. SUBJECTS AND METHODS: Demented PD patients (n=19) were treated with rivastigmine in an open label study. Recordings were obtained prior to and following 12 weeks of treatment. Results were analyzed using two-way ANOVA with repeated measures. RESULTS: A significant increase in the relative alpha (P < 0.05) activity was observed after treatment with rivastigmine. This was general rather than localized to specific brain surface areas. An increase in beta activity and decrease in the slower frequencies (delta and theta) were also observed; however, these were not statistically significant. CONCLUSION: qEEG may serve as an objective tool to monitor the effects of antidementia drug therapy. The changes characterized by increased faster frequencies and decreased slower frequencies that were observed may indicate increased arousal or improvement in the cognitive state of the patients as a consequence of the treatment with rivastigmine.
OBJECTIVES: Quantitative electroencephalogram (qEEG) can be used to measure the effects of drugs on the brain. We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia. SUBJECTS AND METHODS: Demented PDpatients (n=19) were treated with rivastigmine in an open label study. Recordings were obtained prior to and following 12 weeks of treatment. Results were analyzed using two-way ANOVA with repeated measures. RESULTS: A significant increase in the relative alpha (P < 0.05) activity was observed after treatment with rivastigmine. This was general rather than localized to specific brain surface areas. An increase in beta activity and decrease in the slower frequencies (delta and theta) were also observed; however, these were not statistically significant. CONCLUSION: qEEG may serve as an objective tool to monitor the effects of antidementia drug therapy. The changes characterized by increased faster frequencies and decreased slower frequencies that were observed may indicate increased arousal or improvement in the cognitive state of the patients as a consequence of the treatment with rivastigmine.
Authors: Wolfgang Oertel; Werner Poewe; Erik Wolters; Peter Paul De Deyn; Murat Emre; Courtney Kirsch; Chuanchieh Hsu; Sibel Tekin; Roger Lane Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: Nina Benz; Florian Hatz; Habib Bousleiman; Michael M Ehrensperger; Ute Gschwandtner; Martin Hardmeier; Stephan Ruegg; Christian Schindler; Ronan Zimmermann; Andreas Urs Monsch; Peter Fuhr Journal: Front Aging Neurosci Date: 2014-11-18 Impact factor: 5.750
Authors: Meenakshi Dauwan; Jessica J van der Zande; Edwin van Dellen; Iris E C Sommer; Philip Scheltens; Afina W Lemstra; Cornelis J Stam Journal: Alzheimers Dement (Amst) Date: 2016-08-19
Authors: W Poewe; S Gauthier; D Aarsland; J B Leverenz; P Barone; D Weintraub; E Tolosa; B Dubois Journal: Int J Clin Pract Date: 2008-10 Impact factor: 2.503
Authors: Luis R Peraza; Ruth Cromarty; Xenia Kobeleva; Michael J Firbank; Alison Killen; Sara Graziadio; Alan J Thomas; John T O'Brien; John-Paul Taylor Journal: Sci Rep Date: 2018-03-15 Impact factor: 4.379